Resumo

CREO MARTINEZ, T. et al. Long-term roxithromycin treatment for diffuse sclerosing osteomyelitis: a case report. Rev Esp Cirug Oral y Maxilofac [online]. 2005, vol.27, n.6, pp.368-374. ISSN 2173-9161.

Diffuse sclerosing osteomyelitis (DSO) is a disease of unknown etiology which is difficult to diagnose and treat as the literature available on the subject is confused, and there is a considerable lack of knowledge with regards to what causes it and its natural evolution. There are two theories explaining its origin. One suggests an infectious origin, but this is difficult to confirm by means of bacteriological data. The other suggests an osseous hyperplasia origin derived from chronic tendoperiostitis as a result of muscular dysfunction and parafunctional habits. The disease is characterized by recurrent pain and hemimandibular tumefaction, although it can present in other locations. It is accompanied normally by trismus, pressure and paresthesia and regional adenopathy. It has an episodic clinical course. Treating DSO is complex due to the fact that many therapies have been tried but with no long-term success. After reviewing the subject as a result of a clinical case, we recommend considering roxithromycin in the long term as a line of treatment for DSO in view of its efficacy and its tolerable secondary effects. Needless to say, each case should be reviewed individually given the complexity of the disease, while taking into account this therapeutic option.

Palavras-chave : Diffuse sclerosing osteomyelitis; Roxithromycin; Osseous hyperplasia; SAPHO.

        · resumo em Espanhol     · texto em Espanhol | Inglês     · Inglês ( pdf ) | Espanhol ( pdf )